Barricade Therapeutics Investor Webinar | BT-1501 & APC-Mutant Colorectal Cancer

Watch Barricade Therapeutics' investor webinar to learn about BT-1501 and the company's approach to developing a potential new targeted therapy for APC-mutant colorectal cancer. In this recorded webinar, Founder, CEO, CSO, and Board Chairman Dr. Neil Thapar and Fractional Chief Financial Officer Scott Jordan discuss: • The unmet medical need in colorectal cancer • Why APC mutations represent an important therapeutic target • How BT-1501 is being developed to target APC-mutant colorectal cancer • Preclinical progress and recent development milestones • Barricade's strategy for advancing BT-1501 toward clinical development Learn more about Barricade Therapeutics: https://www.barricadetherapeutics.com Learn more about the current investment opportunity: https://www.startengine.com/offering/... Important Information This Reg CF offering is made available through StartEngine Primary, LLC, member FINRA/SIPC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. BT-1501 is an investigational drug candidate that has not been approved by the FDA and has not been proven safe or effective in humans.